Site Map
Pages
Posts
- Vamorolone NDA mid-cycle review meeting by FDA completed
- Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy
- European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
- Santhera and ReveraGen Announce Presentations on Long-Term Efficacy and Bone Health in DMD During Vamorolone Treatment at the 2022 World Muscle Society Congress
- Santhera Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy
- JAMA Neurology Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy
- Santhera and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy
- Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference
- Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
- Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
- Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study
- ReveraGen Receives $3.3 Million NIH Commercialization Readiness Pilot Grant for NDA Preparations for Vamorolone in Duchenne Muscular Dystrophy
- Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy
- Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids
- Santhera Announces Full Enrollment of ReveraGen’s Pivotal VISION-DMD Study with Vamorolone in Duchenne Muscular Dystrophy
- Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
- Jesse’s Journey grants $1M toward the launch of a clinical trial for Duchenne muscular dystrophy in Canada
- ReveraGen BioPharma completes 2.5 years vamorolone treatment of 41 Duchenne muscular dystrophy boys
- ReveraGen BioPharma receives National Institutes of Health ethics grant to return data to participants in vamorolone clinical trials
- Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA
- Vamorolone Designated Promising Innovative Medicine (PIM) for treatment in Duchenne muscular dystrophy
- Top-line data of 18-month vamorolone treatment of Duchenne muscular dystrophy patients shows continued improvement of symptoms with reduction in corticosteroid safety concerns
- Vamorolone Treatment of Duchenne Muscular Dystrophy Patients Leads to Improvements in Motor Function
- Vamorolone (VBP15) First-in-patient Studies in Duchenne Muscular Dystrophy Published
- ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystrophy
- Vamorolone (VBP15) Top Line Data Shows Improvements in Strength and Endurance in Boys with Duchenne Muscular Dystrophy
- Finalists Selected – 3rd Annual BioHealth Capital Region Crab Trap Competition
- ReveraGen BioPharma Receives FDA Fast Track Designation for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
- Actelion obtains an option vamorolone from ReveraGen
- ReveraGen BioPharma Inc Initiates VISION-DMD Phase 2a Study for Treatment of Duchenne Muscular Dystrophy
- ReveraGen BioPharma Receives $3M for Phase 2 Studies of Vamorolone in Duchenne
- Parent Project Muscular Dystrophy and Foundation to Eradicate Duchenne Award $1 Million Grant to ReveraGen BioPharma
- ReveraGen BioPharma Announces Start of Phase 1 Clinical Trial of VBP15 Dissociative Steroid Drug
- January 2015: Action Duchenne announce £55,000 funding for biomarker panel research project
- July 2014: ReveraGen Drug Will Move to Human Testing
- July 2014: International Consortium Provides $2M Funding for Phase 1 Clinical Trial of ReveraGen DMD Drug
- September 2013: VBP15 drug shows early promise for treatment of Duchenne muscular dystrophy
- August 2011: ReveraGen BioPharma Selected as Awardee for Inaugural National Institutes of Health’s Therapeutics for Rare and Neglected Diseases Program for its Novel Dissociative Glucocorticoid Analogue
- August 2011: Former MedImmune exec becomes CEO of startup
